This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Monnat, R. J. Search for Related Content PubMed PubMed Citation Articles by Monnat, R. J., Jr.

Molecular Analysis of Spontaneous Hypoxanthine Phosphoribosyltransferase Mutations in Thioguanine-resistant HL-60 Human Leukemia Cells¹

Department of Pathology SM-30, University of Washington, Seattle, Washington 98195

We have measured the forward mutation rate at the hypoxanthine phosphoribosyltransferase (HPRT) gene of the human promyelocytic leukemia cell line HL-60 and have determined the molecular spectrum of spontaneous HPRT mutations in 45 independent 6-thioguanine-resistant HL-60 sublines. Four fluctuation tests using a total of 132 replicate HL-60 cultures revealed a mean forward mutation rate of HL-60 cells to thioguanine resistance of 1.7–6 x 10^-7/cell/generation. Blot hybridization analysis of the X-linked HPRT gene using a human HPRT complementary DNA probe revealed abnormalities in HPRT gene structure and/or HPRT mRNA expression in 24 of 45 (53%) independent thioguanine-resistant HL-60 sublines. Six different classes of mutation were identified. The most prevalent (47%; 21 of 45 mutations) consists of mutations that are not detected by blot hybridization analyses and that do not disrupt HPRT mRNA production. These results suggest that a comparatively low forward mutation rate may be found in malignant human cells that exhibit both karyotypic and molecular evidence of genomic instability and that several different molecular classes of mutation may contribute to thioguanine resistance in HL-60, and perhaps in other, malignant human cells. The forward mutation assay system we have developed using the X-linked HPRT gene of HL-60 cells may be useful for analyses of the mutagenic potential and molecular spectrum of mutations produced by chemotherapeutic agents, suspected human mutagens and carcinogens, and phagocyte respiratory burst oxidants in human cells.

¹ Supported by NIH Grant 2 POI AG01751, by an Individual Investigator Grant from The University of Washington (Biomedical Research Support Grant RR05432), and by grants from the Harry B. Boyce Fund and the University of Washington Graduate School Research Fund.

Received 6/20/88. Revised 9/19/88. Accepted 9/29/88.

This article has been cited by other articles:

				C. C. Maley, B. J. Reid, and S. Forrest Cancer Prevention Strategies That Address the Evolutionary Dynamics of Neoplastic Cells: Simulating Benign Cell Boosters and Selection for Chemosensitivity Cancer Epidemiol. Biomarkers Prev., August 1, 2004; 13(8): 1375 - 1384. [Abstract] [Full Text] [PDF]

				M. F. Chan, R. van Amerongen, T. Nijjar, E. Cuppen, P. A. Jones, and P. W. Laird Reduced Rates of Gene Loss, Gene Silencing, and Gene Mutation in Dnmt1-Deficient Embryonic Stem Cells Mol. Cell. Biol., November 15, 2001; 21(22): 7587 - 7600. [Abstract] [Full Text] [PDF]

				J. T. Drummond, J. Genschel, E. Wolf, and P. Modrich DHFR/MSH3 amplification in methotrexate-resistant cells alters the hMutSalpha /hMutSbeta ratio and reduces the efficiency of base-base mismatch repair PNAS, September 16, 1997; 94(19): 10144 - 10149. [Abstract] [Full Text] [PDF]

				R Sager Tumor suppressor genes: the puzzle and the promise Science, December 15, 1989; 246(4936): 1406 - 1412. [Abstract] [PDF]